Three more health apps obtained reimbursement in Germany

05

May 2022

In March and April 2022, three more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, thirty-three health apps are now available at the DiGA Directory.

The health app “Meine Tinnitus App - Das digitale Tinnitus Counseling”, developed by Sonormed GmbH, was introduced on March 6, 2022. It provides patients with psycho-education and instructions for self-management through comprehensive tinnitus-specific multimedia content. Within ten weeks, the patients are guided through various lessons in an interactive, entertaining, and individually tailored manner and are gradually familiarized with targeted educational content and exercises. “Meine Tinnitus App - Das digitale Tinnitus Counseling” is a stand-alone therapy for tinnitus patients that follows an initial consultation with the treating physician. The app is available in German with a tariff of €449.

On April 3, 2022, the health app “HelloBetter Panik” (GET.ON Institute for Online Health Training GmbH, Germany) was introduced. “HelloBetter Panik” is an interactive psychological therapy program to treat and reduce the severity of symptoms of panic disorder and agoraphobia with panic disorder. The 12-week online course provides well-founded psychoeducation in text, video, and audio format, as well as effective strategies from cognitive-behavioral therapy (CBT). The app is available in German with a tariff of €599.

The health app “Vitadio”, developed by Vitadio s.r.o., Czech Republic, was introduced on April 15, 2022. “Vitadio” aims to improve diabetes control by empowering users for better self-management and lifestyle. It complements the therapy determined by the doctor and supports patients in achieving their treatment goals and preventing complications associated with diabetes. Users follow an interactive tutorial that covers motivation, nutrition, physical activity, sleep hygiene, psychological well-being, and social aspects of living with diabetes. The app is available in German with a tariff of €499.80.

The full details in German can be found here (Meine Tinnitus App - Das digitale Tinnitus Counseling), here (HelloBetter Panik), and here (Vitadio).

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

20

May 2022

In April 2022, NHS England and NHS Improvement (NHSEI) announced that the timelines for the evaluation of applications to update the National Genomic Test Directory in 2022/23 are currently under review. Previously, NHSEI planned to publish and implement the 2022/23 Test Directory by April 2022. While the timelines are not confirmed, applications can still be submitted.

Read more

19

May 2022

On April 25, 2022, the Decision Forum for "New Method" did not prioritize any surgical procedure in the treatment of morbid obesity. Available evidence in the complete method assessment shows minor or no difference in weight loss, diabetes control, or health-related quality of life when using various surgical procedures. The comparative effect on the risk of early mortality, progression of obesity, and obesity-related comorbidities was not possible to determine. The cost differences are non-significant. Further research was recommended.

Read more

18

May 2022

On April 19, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has informed of the favorable results of the scientific evaluation of the G-BA Innovation Fund performed by the economic research center Prognos AG.

Read more

17

May 2022

On April 21, 2022, NHS England and NHS Improvement updated the 2021/22 National Genomic Test Directory (version 3), which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. Forty-two new codes (test-indication combinations) were introduced in the cancer field, and fourteen for rare and inherited diseases.

Read more

16

May 2022

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in April 2022. Thirty recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular and peripheral vascular, orthopedic, neurovascular, and neuromodulation and other devices, as well as medical aids.

Read more